ERBB2 and neoplasm: Pyrotinib is small, irreversible inhibitor of HER1, HER2, and HER4 molecules that has shown a good preclinical activity in inhibiting HER2-mediated downstream signaling and tumor growth in breast cancer cell lines and xenograft models [39].